368 related articles for article (PubMed ID: 22087078)
1. Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a cost-effectiveness analysis.
Vassall A; van Kampen S; Sohn H; Michael JS; John KR; den Boon S; Davis JL; Whitelaw A; Nicol MP; Gler MT; Khaliqov A; Zamudio C; Perkins MD; Boehme CC; Cobelens F
PLoS Med; 2011 Nov; 8(11):e1001120. PubMed ID: 22087078
[TBL] [Abstract][Full Text] [Related]
2. Population health impact and cost-effectiveness of tuberculosis diagnosis with Xpert MTB/RIF: a dynamic simulation and economic evaluation.
Menzies NA; Cohen T; Lin HH; Murray M; Salomon JA
PLoS Med; 2012; 9(11):e1001347. PubMed ID: 23185139
[TBL] [Abstract][Full Text] [Related]
3. Modeling the patient and health system impacts of alternative xpert® MTB/RIF algorithms for the diagnosis of pulmonary tuberculosis in Addis Ababa, Ethiopia.
Tesfaye A; Fiseha D; Assefa D; Klinkenberg E; Balanco S; Langley I
BMC Infect Dis; 2017 May; 17(1):318. PubMed ID: 28464797
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of novel algorithms for rapid diagnosis of tuberculosis in HIV-infected individuals in Uganda.
Shah M; Dowdy D; Joloba M; Ssengooba W; Manabe YC; Ellner J; Dorman SE
AIDS; 2013 Nov; 27(18):2883-92. PubMed ID: 25119690
[TBL] [Abstract][Full Text] [Related]
5. Microscopic observation drug-susceptibility assay vs. Xpert
Wikman-Jorgensen PE; Llenas-García J; Pérez-Porcuna TM; Hobbins M; Ehmer J; Mussa MA; Ascaso C
Trop Med Int Health; 2017 Jun; 22(6):734-743. PubMed ID: 28380276
[TBL] [Abstract][Full Text] [Related]
6. Delayed diagnosis and treatment of tuberculosis in HIV+ patients in Mozambique: A cost-effectiveness analysis of screening protocols based on four symptom screening, smear microscopy, urine LAM test and Xpert MTB/RIF.
Orlando S; Triulzi I; Ciccacci F; Palla I; Palombi L; Marazzi MC; Giuliano M; Floridia M; Mancinelli S; Mutemba E; Turchetti G
PLoS One; 2018; 13(7):e0200523. PubMed ID: 30024890
[TBL] [Abstract][Full Text] [Related]
7. Optimal triage test characteristics to improve the cost-effectiveness of the Xpert MTB/RIF assay for TB diagnosis: a decision analysis.
van't Hoog AH; Cobelens F; Vassall A; van Kampen S; Dorman SE; Alland D; Ellner J
PLoS One; 2013; 8(12):e82786. PubMed ID: 24367555
[TBL] [Abstract][Full Text] [Related]
8. Point-of-care Xpert® MTB/RIF for smear-negative tuberculosis suspects at a primary care clinic in South Africa.
Van Rie A; Page-Shipp L; Hanrahan CF; Schnippel K; Dansey H; Bassett J; Clouse K; Scott L; Stevens W; Sanne I
Int J Tuberc Lung Dis; 2013 Mar; 17(3):368-72. PubMed ID: 23407225
[TBL] [Abstract][Full Text] [Related]
9. Costs and cost-effectiveness of Gene Xpert compared to smear microscopy for the diagnosis of pulmonary tuberculosis using real-world data from Arsi zone, Ethiopia.
Kaso AW; Hailu A
PLoS One; 2021; 16(10):e0259056. PubMed ID: 34695153
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of microscopic observation drug susceptibility test versus Xpert MTB/Rif test for diagnosis of pulmonary tuberculosis in HIV patients in Uganda.
Walusimbi S; Kwesiga B; Rodrigues R; Haile M; de Costa A; Bogg L; Katamba A
BMC Health Serv Res; 2016 Oct; 16(1):563. PubMed ID: 27724908
[TBL] [Abstract][Full Text] [Related]
11. Point of care Xpert MTB/RIF versus smear microscopy for tuberculosis diagnosis in southern African primary care clinics: a multicentre economic evaluation.
Pooran A; Theron G; Zijenah L; Chanda D; Clowes P; Mwenge L; Mutenherwa F; Lecesse P; Metcalfe J; Sohn H; Hoelscher M; Pym A; Peter J; Dowdy D; Dheda K
Lancet Glob Health; 2019 Jun; 7(6):e798-e807. PubMed ID: 31097281
[TBL] [Abstract][Full Text] [Related]
12. Cost-benefit analysis of Xpert MTB/RIF for tuberculosis suspects in German hospitals.
Diel R; Nienhaus A; Hillemann D; Richter E
Eur Respir J; 2016 Feb; 47(2):575-87. PubMed ID: 26647440
[TBL] [Abstract][Full Text] [Related]
13. Rapid, point-of-care diagnosis of tuberculosis with novel Truenat assay: Cost-effectiveness analysis for India's public sector.
Lee DJ; Kumarasamy N; Resch SC; Sivaramakrishnan GN; Mayer KH; Tripathy S; Paltiel AD; Freedberg KA; Reddy KP
PLoS One; 2019; 14(7):e0218890. PubMed ID: 31265470
[TBL] [Abstract][Full Text] [Related]
14. Comparing laboratory costs of smear/culture and Xpert
Naidoo P; Dunbar R; du Toit E; van Niekerk M; Squire SB; Beyers N; Madan J
Int J Tuberc Lung Dis; 2016 Oct; 20(10):1377-1385. PubMed ID: 27725051
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study.
Scott LE; McCarthy K; Gous N; Nduna M; Van Rie A; Sanne I; Venter WF; Duse A; Stevens W
PLoS Med; 2011 Jul; 8(7):e1001061. PubMed ID: 21814495
[TBL] [Abstract][Full Text] [Related]
16. Burden of tuberculosis in intensive care units in Cape Town, South Africa, and assessment of the accuracy and effect on patient outcomes of the Xpert MTB/RIF test on tracheal aspirate samples for diagnosis of pulmonary tuberculosis: a prospective burden of disease study with a nested randomised controlled trial.
Calligaro GL; Theron G; Khalfey H; Peter J; Meldau R; Matinyenya B; Davids M; Smith L; Pooran A; Lesosky M; Esmail A; Miller MG; Piercy J; Michell L; Dawson R; Raine RI; Joubert I; Dheda K
Lancet Respir Med; 2015 Aug; 3(8):621-30. PubMed ID: 26208996
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting.
Theron G; Peter J; van Zyl-Smit R; Mishra H; Streicher E; Murray S; Dawson R; Whitelaw A; Hoelscher M; Sharma S; Pai M; Warren R; Dheda K
Am J Respir Crit Care Med; 2011 Jul; 184(1):132-40. PubMed ID: 21493734
[TBL] [Abstract][Full Text] [Related]
18. The cost-effectiveness of routine tuberculosis screening with Xpert MTB/RIF prior to initiation of antiretroviral therapy: a model-based analysis.
Andrews JR; Lawn SD; Rusu C; Wood R; Noubary F; Bender MA; Horsburgh CR; Losina E; Freedberg KA; Walensky RP
AIDS; 2012 May; 26(8):987-95. PubMed ID: 22333751
[TBL] [Abstract][Full Text] [Related]
19. Accuracy of different Xpert MTB/Rif implementation strategies in programmatic settings at the regional referral hospitals in Uganda: Evidence for country wide roll out.
Muttamba W; Ssengooba W; Sekibira R; Kirenga B; Katamba A; Joloba M
PLoS One; 2018; 13(3):e0194741. PubMed ID: 29566056
[TBL] [Abstract][Full Text] [Related]
20. Optimizing tuberculosis case detection through a novel diagnostic device placement model: the case of Uganda.
Pho MT; Deo S; Palamountain KM; Joloba ML; Bajunirwe F; Katamba A
PLoS One; 2015; 10(4):e0122574. PubMed ID: 25830297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
